Amgen Inc (AMGN)

174.45
0.44 0.25
NASDAQ : Health Care
Prev Close 174.01
Open 173.29
Day Low/High 172.48 / 174.72
52 Wk Low/High 130.09 / 181.81
Volume 2.67M
Avg Volume 3.62M
Exchange NASDAQ
Shares Outstanding 736.45M
Market Cap 127.12B
EPS 10.30
P/E Ratio 16.86
Div & Yield 4.60 (2.70%)

Latest News

Amgen Shows a Bullish Breakout

Amgen Shows a Bullish Breakout

There is more upside to come for this stock.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Chart of the Day: Amgen

There is more upside to come for this stock.

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Here's How the Tom Price Stock Portfolio Is Performing Now That He Is Confirmed

Tom Price will now head the Department of Health and Human Services.

Dividend Hikes and Must-Own Dates

Interpublic and United Parcel raise dividends, and a recap of notable dates.

Bonds Call the Tune Today, Not Stocks: Cramer's 'Mad Money' Recap (Thursday 2/9/17)

Bonds Call the Tune Today, Not Stocks: Cramer's 'Mad Money' Recap (Thursday 2/9/17)

When bond yields rise, the economy roars and it's game on for industrials, banks and retailers, says Jim Cramer.

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

Barclays, Banco Santander, Amgen, UnitedHealth Group: 'Mad Money' Lightning Round

Barclays, Banco Santander, Amgen, UnitedHealth Group: 'Mad Money' Lightning Round

Jim Cramer likes European banks, plus Banco Santander, and New York Community Bancorp, too.

Analyzing Risks Posed by a Possible Trump Correction: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Analyzing Risks Posed by a Possible Trump Correction: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Jim Cramer takes a closer look at the risks: Don't measure 'Trump per share,' measure actual earnings per share.

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study

Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study

The outcome of the so-called 'FOURIER' trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha.

House Panel to Take Up Trump's Call to Speed FDA Approvals

House Panel to Take Up Trump's Call to Speed FDA Approvals

Generics for drugs facing shortages or having few manufacturers is bill's focus.

Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Cytokinetics, Achillion and Qiagen were among the biotech stock movers in premarket trading on Thursday.

There Is So Little Attention Paid to the Fed Meeting

There Is So Little Attention Paid to the Fed Meeting

The Fed is simply not a market catalyst this time.

Trump, at Biopharma Meeting, Pledges to 'Streamline' FDA, Cut Regulations but Wants Lower Prices

Trump, at Biopharma Meeting, Pledges to 'Streamline' FDA, Cut Regulations but Wants Lower Prices

Biotech and drugs stocks are soaring Tuesday after President Donald Trump met with CEOs of the biotech and pharma industries Tuesday.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

The Market Is Frothy Up Here

We are moderately overbought, both on a short-term and an intermediate-term basis.

Week Ahead: Apple Earnings Headline Busy Week of Fed Meetings, Jobs Numbers

Week Ahead: Apple Earnings Headline Busy Week of Fed Meetings, Jobs Numbers

Buckle in for a busy week filled with bellwether earnings reports, monetary policy decisions, and closely scrutinized economic numbers.

Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

First Adalimumab Biosimilar Candidate Recommended for EMA Approval

Nike, Disney, Amgen: When Charts, Fundamentals Don't Match

Nike, Disney, Amgen: When Charts, Fundamentals Don't Match

There's not much reason to be bullish on these stocks.